{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T11:42:38Z","timestamp":1792755758618,"version":"4.5.0"},"reference-count":75,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","pet.theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["PET Clinics"],"published-print":{"date-parts":[[2024,7]]},"DOI":"10.1016\/j.cpet.2024.03.010","type":"journal-article","created":{"date-parts":[[2024,5,28]],"date-time":"2024-05-28T21:04:09Z","timestamp":1716930249000},"page":"431-446","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["Hepatic Radioembolization"],"prefix":"10.1016","volume":"19","author":[{"given":"Khalil","family":"Ramdhani","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marnix G.E.H.","family":"Lam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arthur J.A.T.","family":"Braat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maarten L.J.","family":"Smits","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ghassan","family":"El-Haddad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.cpet.2024.03.010_bib1","first-page":"969","article-title":"The blood supply of neoplasms in the liver","volume":"30","author":"Breedis","year":"1954","journal-title":"Am J Pathol"},{"issue":"2","key":"10.1016\/j.cpet.2024.03.010_bib2","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1097\/00000658-196508000-00018","article-title":"Treatment of inoperable primary pancreatic and liver cancer by the intra-arterial administration of radioactive isotopes (y90 radiating microspheres)","volume":"162","author":"Ariel","year":"1965","journal-title":"Ann Surg"},{"issue":"7","key":"10.1016\/j.cpet.2024.03.010_bib3","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1097\/MNM.0000000000001026","article-title":"History and development of radioembolization: an old idea with modern applications","volume":"40","author":"Spyridonidis","year":"2019","journal-title":"Nucl Med Commun"},{"issue":"4","key":"10.1016\/j.cpet.2024.03.010_bib4","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/j.adro.2016.08.003","article-title":"The development, commercialization, and clinical context of yttrium-90 radiolabeled resin and glass microspheres","volume":"1","author":"Westcott","year":"2016","journal-title":"Adv Radiat Oncol"},{"issue":"5","key":"10.1016\/j.cpet.2024.03.010_bib5","doi-asserted-by":"crossref","first-page":"1682","DOI":"10.1007\/s00259-021-05600-z","article-title":"EANM procedure guideline for the treatment of liver cancer and liver metastases with intra-arterial radioactive compounds","volume":"49","author":"Weber","year":"2022","journal-title":"Eur J Nucl Med Mol Imag"},{"issue":"8","key":"10.1016\/j.cpet.2024.03.010_bib6","doi-asserted-by":"crossref","first-page":"1294","DOI":"10.2967\/jnumed.112.117614","article-title":"99mTc-macroaggregated albumin poorly predicts the intrahepatic distribution of 90Y resin microspheres in hepatic radioembolization","volume":"54","author":"Wondergem","year":"2013","journal-title":"J\u00a0Nucl Med"},{"issue":"11","key":"10.1016\/j.cpet.2024.03.010_bib7","doi-asserted-by":"crossref","first-page":"1654","DOI":"10.2967\/jnumed.115.162685","article-title":"Predictive value of 99mTc-MAA SPECT for 90Y-labeled resin microsphere distribution in radioembolization of primary and secondary hepatic tumors","volume":"56","author":"Ilhan","year":"2015","journal-title":"J\u00a0Nucl Med"},{"issue":"3","key":"10.1016\/j.cpet.2024.03.010_bib8","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1148\/radiol.2020191606","article-title":"Relationship of tumor radiation-absorbed dose to survival and response in hepatocellular carcinoma treated with transarterial radioembolization with (90)y in the sarah study","volume":"296","author":"Hermann","year":"2020","journal-title":"Radiology"},{"issue":"10","key":"10.1016\/j.cpet.2024.03.010_bib9","doi-asserted-by":"crossref","first-page":"1965","DOI":"10.1007\/s00259-014-2784-9","article-title":"(\u2079\u2079m)Tc-MAA overestimates the absorbed dose to the lungs in radioembolization: a quantitative evaluation in patients treated with 1\u2076\u2076Ho-microspheres","volume":"41","author":"Elschot","year":"2014","journal-title":"Eur J Nucl Med Mol Imag"},{"issue":"4","key":"10.1016\/j.cpet.2024.03.010_bib10","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1007\/s00259-019-04460-y","article-title":"The superior predictive value of (166)Ho-scout compared with (99m)Tc-macroaggregated albumin prior to (166)Ho-microspheres radioembolization in patients with liver metastases","volume":"47","author":"Smits","year":"2020","journal-title":"Eur J Nucl Med Mol Imag"},{"issue":"10","key":"10.1016\/j.cpet.2024.03.010_bib11","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1016\/S1470-2045(12)70334-0","article-title":"Holmium-166 radioembolisation in patients with unresectable, chemorefractory liver metastases (HEPAR trial): a phase 1, dose-escalation study","volume":"13","author":"Smits","year":"2012","journal-title":"Lancet Oncol"},{"issue":"6","key":"10.1016\/j.cpet.2024.03.010_bib12","doi-asserted-by":"crossref","first-page":"817","DOI":"10.2967\/jnumed.115.155564","article-title":"Safety of a scout dose preceding hepatic radioembolization with 166Ho microspheres","volume":"56","author":"Prince","year":"2015","journal-title":"J\u00a0Nucl Med"},{"issue":"3","key":"10.1016\/j.cpet.2024.03.010_bib13","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1007\/s00330-017-4998-2","article-title":"Safety analysis of holmium-166 microsphere scout dose imaging during radioembolisation work-up: a cohort study","volume":"28","author":"Braat","year":"2018","journal-title":"Eur Radiol"},{"issue":"7","key":"10.1016\/j.cpet.2024.03.010_bib14","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1016\/j.jvir.2023.03.011","article-title":"Evolution of personalized dosimetry for radioembolization of hepatocellular carcinoma","volume":"34","author":"Knight","year":"2023","journal-title":"J\u00a0Vasc Intervent Radiol"},{"issue":"5","key":"10.1016\/j.cpet.2024.03.010_bib15","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1055\/s-0041-1736660","article-title":"Beyond the MAA-Y90 Paradigm: the evolution of radioembolization dosimetry approaches and scout particles","volume":"38","author":"Keane","year":"2021","journal-title":"Semin Intervent Radiol"},{"issue":"1","key":"10.1016\/j.cpet.2024.03.010_bib16","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1186\/s40658-020-00343-6","article-title":"Impact of the dosimetry approach on the resulting (90)Y radioembolization planned absorbed doses based on (99m)Tc-MAA SPECT-CT: is there agreement between dosimetry methods?","volume":"7","author":"Mor\u00e1n","year":"2020","journal-title":"EJNMMI Phys"},{"issue":"4","key":"10.1016\/j.cpet.2024.03.010_bib17","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1016\/j.ijrobp.2016.07.021","article-title":"Selective internal radiation therapy with yttrium-90 glass microspheres: biases and uncertainties in absorbed dose calculations between clinical dosimetry models","volume":"96","author":"Mikell","year":"2016","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"1","key":"10.1016\/j.cpet.2024.03.010_bib18","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1186\/s40658-018-0221-z","article-title":"The physics of radioembolization","volume":"5","author":"Bastiaannet","year":"2018","journal-title":"EJNMMI Phys"},{"issue":"10","key":"10.1016\/j.cpet.2024.03.010_bib19","doi-asserted-by":"crossref","first-page":"3340","DOI":"10.1007\/s00259-022-05774-0","article-title":"A\u00a0global evaluation of advanced dosimetry in transarterial radioembolization of hepatocellular carcinoma with Yttrium-90: the TARGET study","volume":"49","author":"Lam","year":"2022","journal-title":"Eur J Nucl Med Mol Imag"},{"issue":"12","key":"10.1016\/j.cpet.2024.03.010_bib20","doi-asserted-by":"crossref","first-page":"2138","DOI":"10.1016\/j.jvir.2023.08.031","article-title":"Predictive partition dosimetry and outcomes after yttrium-90 resin microsphere radioembolization of colorectal cancer metastatic to the liver: a retrospective analysis","volume":"34","author":"Doyle","year":"2023","journal-title":"J\u00a0Vasc Intervent Radiol"},{"issue":"1","key":"10.1016\/j.cpet.2024.03.010_bib21","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/S2468-1253(20)30290-9","article-title":"Personalised vs standard dosimetry approach of selective internal radiation therapy in patients with locally advanced hepatocellular carcinoma (DOSISPHERE-01): a randomised, multicentre, open-label phase 2 trial","volume":"6","author":"Garin","year":"2021","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"2","key":"10.1016\/j.cpet.2024.03.010_bib22","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.clon.2020.12.003","article-title":"Current status and future direction of hepatic radioembolisation","volume":"33","author":"Alsultan","year":"2021","journal-title":"Clin Oncol"},{"issue":"2","key":"10.1016\/j.cpet.2024.03.010_bib23","doi-asserted-by":"crossref","first-page":"192","DOI":"10.15403\/jgld-3478","article-title":"Holmium-166 microspheres are visible in target liver lesions on unenhanced computed tomography","volume":"30","author":"Bonne","year":"2021","journal-title":"J\u00a0Gastrointestin Liver Dis"},{"issue":"7","key":"10.1016\/j.cpet.2024.03.010_bib24","doi-asserted-by":"crossref","first-page":"1831","DOI":"10.3390\/biomedicines11071831","article-title":"Clinical results of transarterial radioembolization (tare) with holmium-166 microspheres in the multidisciplinary oncologic treatment of patients with primary and secondary liver cancer","volume":"11","author":"Drescher","year":"2023","journal-title":"Biomedicines"},{"issue":"10","key":"10.1016\/j.cpet.2024.03.010_bib25","doi-asserted-by":"crossref","first-page":"1593","DOI":"10.1016\/j.jvir.2020.01.032","article-title":"Evaluation of the safety and feasibility of same-day holmium-166 -radioembolization simulation and treatment of hepatic metastases","volume":"31","author":"van Roekel","year":"2020","journal-title":"J\u00a0Vasc Intervent Radiol"},{"issue":"1062","key":"10.1016\/j.cpet.2024.03.010_bib26","doi-asserted-by":"crossref","first-page":"20150943","DOI":"10.1259\/bjr.20150943","article-title":"Yttrium-90 hepatic radioembolization: clinical review and current techniques in interventional radiology and personalized dosimetry","volume":"89","author":"Tong","year":"2016","journal-title":"Br J Radiol"},{"issue":"1","key":"10.1016\/j.cpet.2024.03.010_bib27","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1038\/s41572-020-00240-3","article-title":"Hepatocellular carcinoma","volume":"7","author":"Llovet","year":"2021","journal-title":"Nat Rev Dis Primers"},{"issue":"15","key":"10.1016\/j.cpet.2024.03.010_bib28","doi-asserted-by":"crossref","first-page":"1450","DOI":"10.1056\/NEJMra1713263","article-title":"Hepatocellular carcinoma","volume":"380","author":"Villanueva","year":"2019","journal-title":"N\u00a0Engl J Med"},{"issue":"12","key":"10.1016\/j.cpet.2024.03.010_bib29","doi-asserted-by":"crossref","first-page":"1624","DOI":"10.1016\/S1470-2045(17)30683-6","article-title":"Efficacy and safety of selective internal radiotherapy with yttrium-90 resin microspheres compared with sorafenib in locally advanced and inoperable hepatocellular carcinoma (SARAH): an open-label randomised controlled phase 3 trial","volume":"18","author":"Vilgrain","year":"2017","journal-title":"Lancet Oncol"},{"issue":"19","key":"10.1016\/j.cpet.2024.03.010_bib30","doi-asserted-by":"crossref","first-page":"1913","DOI":"10.1200\/JCO.2017.76.0892","article-title":"SIRveNIB: selective internal radiation therapy versus sorafenib in asia-pacific patients with hepatocellular carcinoma","volume":"36","author":"Chow","year":"2018","journal-title":"J\u00a0Clin Oncol"},{"issue":"6","key":"10.1016\/j.cpet.2024.03.010_bib31","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1016\/j.jhep.2019.08.006","article-title":"Impact of combined selective internal radiation therapy and sorafenib on survival in advanced hepatocellular carcinoma","volume":"71","author":"Ricke","year":"2019","journal-title":"J\u00a0Hepatol"},{"issue":"20","key":"10.1016\/j.cpet.2024.03.010_bib32","doi-asserted-by":"crossref","first-page":"1894","DOI":"10.1056\/NEJMoa1915745","article-title":"Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma","volume":"382","author":"Finn","year":"2020","journal-title":"N\u00a0Engl J Med"},{"issue":"12","key":"10.1016\/j.cpet.2024.03.010_bib33","doi-asserted-by":"crossref","first-page":"1891","DOI":"10.2967\/jnumed.122.263823","article-title":"Safety and efficacy of (166)ho radioembolization in hepatocellular carcinoma: the hepar primary study","volume":"63","author":"Reinders","year":"2022","journal-title":"J\u00a0Nucl Med"},{"issue":"5","key":"10.1016\/j.cpet.2024.03.010_bib34","doi-asserted-by":"crossref","first-page":"2342","DOI":"10.1002\/hep.31819","article-title":"Yttrium-90 radioembolization for the treatment of solitary, unresectable HCC: the LEGACY study","volume":"74","author":"Salem","year":"2021","journal-title":"Hepatology"},{"issue":"3","key":"10.1016\/j.cpet.2024.03.010_bib35","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1016\/j.jhep.2021.11.018","article-title":"BCLC strategy for prognosis prediction and treatment recommendation: the 2022 update","volume":"76","author":"Reig","year":"2022","journal-title":"J\u00a0Hepatol"},{"issue":"34","key":"10.1016\/j.cpet.2024.03.010_bib36","doi-asserted-by":"crossref","first-page":"55368","DOI":"10.18632\/oncotarget.10552","article-title":"Incidence and origin of histologically confirmed liver metastases: an explorative case-study of 23,154 patients","volume":"7","author":"de Ridder","year":"2016","journal-title":"Oncotarget"},{"issue":"23","key":"10.1016\/j.cpet.2024.03.010_bib37","doi-asserted-by":"crossref","first-page":"3687","DOI":"10.1200\/JCO.2010.28.5643","article-title":"Phase III trial comparing protracted intravenous fluorouracil infusion alone or with yttrium-90 resin microspheres radioembolization for liver-limited metastatic colorectal cancer refractory to standard chemotherapy","volume":"28","author":"Hendlisz","year":"2010","journal-title":"J\u00a0Clin Oncol"},{"issue":"9","key":"10.1016\/j.cpet.2024.03.010_bib38","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1016\/S1470-2045(17)30457-6","article-title":"First-line selective internal radiotherapy plus chemotherapy versus chemotherapy alone in patients with liver metastases from colorectal cancer (FOXFIRE, SIRFLOX, and FOXFIRE-Global): a combined analysis of three multicentre, randomised, phase 3 trials","volume":"18","author":"Wasan","year":"2017","journal-title":"Lancet Oncol"},{"issue":"15","key":"10.1016\/j.cpet.2024.03.010_bib39","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1200\/JCO.2015.66.1181","article-title":"SIRFLOX: randomized phase III trial comparing first-line mFOLFOX6 (plus or minus bevacizumab) versus mFOLFOX6 (plus or minus bevacizumab) plus selective internal radiation therapy in patients with metastatic colorectal cancer","volume":"34","author":"van Hazel","year":"2016","journal-title":"J\u00a0Clin Oncol"},{"issue":"4","key":"10.1016\/j.cpet.2024.03.010_bib40","doi-asserted-by":"crossref","first-page":"e617","DOI":"10.1016\/j.clcc.2018.06.001","article-title":"Effect of primary tumor side on survival outcomes in untreated patients with metastatic colorectal cancer when selective internal radiation therapy is added to chemotherapy: combined analysis of two randomized controlled studies","volume":"17","author":"Gibbs","year":"2018","journal-title":"Clin Colorectal Cancer"},{"issue":"35","key":"10.1016\/j.cpet.2024.03.010_bib41","doi-asserted-by":"crossref","first-page":"3897","DOI":"10.1200\/JCO.21.01839","article-title":"Radioembolization with chemotherapy for colorectal liver metastases: a randomized, open-label, international, multicenter, phase III trial","volume":"39","author":"Mulcahy","year":"2021","journal-title":"J\u00a0Clin Oncol"},{"issue":"11","key":"10.1016\/j.cpet.2024.03.010_bib42","doi-asserted-by":"crossref","first-page":"1634","DOI":"10.1007\/s00270-022-03187-y","article-title":"Holmium-166 radioembolization: current status and future prospective","volume":"45","author":"Stella","year":"2022","journal-title":"Cardiovasc Intervent Radiol"},{"issue":"1","key":"10.1016\/j.cpet.2024.03.010_bib43","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.annonc.2022.10.003","article-title":"Metastatic colorectal cancer: ESMO clinical practice guideline for diagnosis, treatment and follow-up","volume":"34","author":"Cervantes","year":"2023","journal-title":"Ann Oncol"},{"issue":"4","key":"10.1016\/j.cpet.2024.03.010_bib44","first-page":"216","article-title":"Combining selective internal radiation therapy with immunotherapy in treating hepatocellular carcinoma and hepatic colorectal metastases: a systematic review","volume":"38","author":"Ramdhani","year":"2023","journal-title":"Cancer Biother Radiopharm"},{"issue":"12","key":"10.1016\/j.cpet.2024.03.010_bib45","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1016\/j.neo.2017.09.002","article-title":"Nothing but NET: a review of neuroendocrine tumors and carcinomas","volume":"19","author":"Oronsky","year":"2017","journal-title":"Neoplasia"},{"issue":"1","key":"10.1016\/j.cpet.2024.03.010_bib46","doi-asserted-by":"crossref","first-page":"R75","DOI":"10.1677\/ERC-09-0108","article-title":"Systemic therapy for neuroendocrine tumours of gastroenteropancreatic origin","volume":"17","author":"Basu","year":"2010","journal-title":"Endocr Relat Cancer"},{"issue":"10","key":"10.1016\/j.cpet.2024.03.010_bib47","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1001\/jamaoncol.2017.0589","article-title":"Trends in the incidence, prevalence, and survival outcomes in patients with neuroendocrine tumors in the United States","volume":"3","author":"Dasari","year":"2017","journal-title":"JAMA Oncol"},{"issue":"12","key":"10.1016\/j.cpet.2024.03.010_bib48","doi-asserted-by":"crossref","first-page":"2679","DOI":"10.1002\/ijc.30400","article-title":"The epidemiology of metastases in neuroendocrine tumors","volume":"139","author":"Riihim\u00e4ki","year":"2016","journal-title":"Int J Cancer"},{"issue":"14","key":"10.1016\/j.cpet.2024.03.010_bib49","doi-asserted-by":"crossref","first-page":"3415","DOI":"10.3390\/cancers14143415","article-title":"The evolving role of radioembolization in the treatment of neuroendocrine liver metastases","volume":"14","author":"Ramdhani","year":"2022","journal-title":"Cancers (Basel)"},{"issue":"5","key":"10.1016\/j.cpet.2024.03.010_bib50","first-page":"679","article-title":"90Y Radioembolization in the treatment of neuroendocrine neoplasms: results of an international multicenter retrospective study","volume":"63","author":"Schaarschmidt","year":"2022","journal-title":"J\u00a0Nucl Med"},{"issue":"8","key":"10.1016\/j.cpet.2024.03.010_bib51","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1097\/MPA.0000000000001115","article-title":"Safety and feasibility of integrating Yttrium-90 radioembolization with capecitabine-temozolomide for grade 2 liver-dominant metastatic neuroendocrine tumors","volume":"47","author":"Soulen","year":"2018","journal-title":"Pancreas"},{"issue":"9","key":"10.1016\/j.cpet.2024.03.010_bib52","doi-asserted-by":"crossref","first-page":"1992","DOI":"10.1002\/cncr.31192","article-title":"Phase 1b study of pasireotide, everolimus, and selective internal radioembolization therapy for unresectable neuroendocrine tumors with hepatic metastases","volume":"124","author":"Kim","year":"2018","journal-title":"Cancer"},{"issue":"1","key":"10.1016\/j.cpet.2024.03.010_bib53","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1186\/s12876-018-0817-8","article-title":"Additional hepatic (166)Ho-radioembolization in patients with neuroendocrine tumours treated with (177)Lu-DOTATATE; a single center, interventional, non-randomized, non-comparative, open label, phase II study (HEPAR PLUS trial)","volume":"18","author":"Braat","year":"2018","journal-title":"BMC Gastroenterol"},{"issue":"1","key":"10.1016\/j.cpet.2024.03.010_bib54","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1186\/s12885-022-09302-z","article-title":"Long-term outcomes following 90Y Radioembolization of neuroendocrine liver metastases: evaluation of the radiation-emitting SIR-spheres in non-resectable liver tumor (RESiN) registry","volume":"22","author":"Wong","year":"2022","journal-title":"BMC Cancer"},{"issue":"2","key":"10.1016\/j.cpet.2024.03.010_bib55","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1159\/000443167","article-title":"ENETS consensus guidelines update for the management of distant metastatic disease of intestinal, pancreatic, bronchial neuroendocrine neoplasms (NEN) and NEN of unknown primary site","volume":"103","author":"Pavel","year":"2016","journal-title":"Neuroendocrinology"},{"issue":"7","key":"10.1016\/j.cpet.2024.03.010_bib56","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1016\/j.annonc.2020.03.304","article-title":"Gastroenteropancreatic neuroendocrine neoplasms: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"31","author":"Pavel","year":"2020","journal-title":"Ann Oncol"},{"issue":"9","key":"10.1016\/j.cpet.2024.03.010_bib57","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1016\/j.jvir.2023.05.026","article-title":"Radioembolization with Yttrium-90 glass microspheres as a first-line treatment for unresectable intrahepatic cholangiocarcinoma-a prospective feasibility study","volume":"34","author":"Kis","year":"2023","journal-title":"J\u00a0Vasc Intervent Radiol"},{"issue":"7","key":"10.1016\/j.cpet.2024.03.010_bib58","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1002\/bjs.10676","article-title":"Early versus late recurrence of intrahepatic cholangiocarcinoma after resection with curative intent","volume":"105","author":"Zhang","year":"2018","journal-title":"Br J Surg"},{"issue":"4","key":"10.1016\/j.cpet.2024.03.010_bib59","doi-asserted-by":"crossref","first-page":"529","DOI":"10.2967\/jnumed.122.264598","article-title":"Real-life experience in the treatment of intrahepatic cholangiocarcinoma by 90y radioembolization: a multicenter retrospective study","volume":"64","author":"Benedikt","year":"2023","journal-title":"J\u00a0Nucl Med"},{"issue":"1","key":"10.1016\/j.cpet.2024.03.010_bib60","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jvir.2016.09.024","article-title":"Radioembolization of hepatic malignancies: background, quality improvement guidelines, and future directions","volume":"28","author":"Padia","year":"2017","journal-title":"J\u00a0Vasc Intervent Radiol"},{"issue":"9","key":"10.1016\/j.cpet.2024.03.010_bib61","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1007\/s00270-020-02569-4","article-title":"Yttrium-90 radioembolization in unresectable intrahepatic cholangiocarcinoma: results of a multicenter retrospective study","volume":"43","author":"Bargellini","year":"2020","journal-title":"Cardiovasc Intervent Radiol"},{"issue":"9","key":"10.1016\/j.cpet.2024.03.010_bib62","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1016\/j.jvir.2023.05.026","article-title":"Radioembolization with Yttrium-90 Glass Microspheres as a First-Line Treatment for Unresectable Intrahepatic Cholangiocarcinoma-A Prospective Feasibility Study","volume":"34","author":"Kis","year":"2023","journal-title":"J Vasc Interv Radiol"},{"issue":"11","key":"10.1016\/j.cpet.2024.03.010_bib63","doi-asserted-by":"crossref","first-page":"1641","DOI":"10.1007\/s00270-020-02612-4","article-title":"Intra-hepatic abscopal effect following radioembolization of hepatic metastases","volume":"43","author":"Powerski","year":"2020","journal-title":"Cardiovasc Intervent Radiol"},{"issue":"11","key":"10.1016\/j.cpet.2024.03.010_bib64","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.1016\/j.jvir.2020.07.009","article-title":"Safety and efficacy of locoregional treatment during immunotherapy with nivolumab for hepatocellular carcinoma: a retrospective study of 41 interventions in 29 patients","volume":"31","author":"Marinelli","year":"2020","journal-title":"J\u00a0Vasc Intervent Radiol"},{"issue":"6","key":"10.1016\/j.cpet.2024.03.010_bib65","doi-asserted-by":"crossref","first-page":"863","DOI":"10.2214\/AJR.22.28800","article-title":"Cancer immunology: impact of radioembolization of hepatocellular carcinoma on immune response modulation","volume":"220","author":"Torkian","year":"2023","journal-title":"AJR Am J Roentgenol"},{"issue":"6","key":"10.1016\/j.cpet.2024.03.010_bib66","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1080\/17474124.2023.2215981","article-title":"Integrated use of (90)Y-labeled microspheres and immune checkpoint inhibitors in hepatic tumors: current status and future directions","volume":"17","author":"Filippi","year":"2023","journal-title":"Expet Rev Gastroenterol Hepatol"},{"issue":"2","key":"10.1016\/j.cpet.2024.03.010_bib67","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1056\/NEJMoa1607427","article-title":"Phase 3 Trial of (177)Lu-dotatate for midgut neuroendocrine tumors","volume":"376","author":"Strosberg","year":"2017","journal-title":"N\u00a0Engl J Med"},{"issue":"12","key":"10.1016\/j.cpet.2024.03.010_bib68","doi-asserted-by":"crossref","first-page":"1752","DOI":"10.1016\/S1470-2045(21)00572-6","article-title":"(177)Lu-Dotatate plus long-acting octreotide versus high-dose long-acting octreotide in patients with midgut neuroendocrine tumours (NETTER-1): final overall survival and long-term safety results from an open-label, randomised, controlled, phase 3 trial","volume":"22","author":"Strosberg","year":"2021","journal-title":"Lancet Oncol"},{"issue":"2","key":"10.1016\/j.cpet.2024.03.010_bib69","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1007\/s00270-019-02350-2","article-title":"Radioembolization with (90)Y resin microspheres of neuroendocrine liver metastases after initial peptide receptor radionuclide therapy","volume":"43","author":"Braat","year":"2020","journal-title":"Cardiovasc Intervent Radiol"},{"issue":"4","key":"10.1016\/j.cpet.2024.03.010_bib70","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1016\/S1470-2045(20)30027-9","article-title":"Additional holmium-166 radioembolisation after lutetium-177-dotatate in patients with neuroendocrine tumour liver metastases (HEPAR PLuS): a single-centre, single-arm, open-label, phase 2 study","volume":"21","author":"Braat","year":"2020","journal-title":"Lancet Oncol"},{"issue":"3","key":"10.1016\/j.cpet.2024.03.010_bib71","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1148\/radiol.2018171768","article-title":"Radiation segmentectomy: potential curative therapy for early hepatocellular carcinoma","volume":"287","author":"Lewandowski","year":"2018","journal-title":"Radiology"},{"issue":"9","key":"10.1016\/j.cpet.2024.03.010_bib72","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1016\/S2468-1253(22)00091-7","article-title":"Radiation segmentectomy for curative intent of unresectable very early to early stage hepatocellular carcinoma (RASER): a single-centre, single-arm study","volume":"7","author":"Kim","year":"2022","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"1","key":"10.1016\/j.cpet.2024.03.010_bib73","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1080\/02656736.2021.1933215","article-title":"Yttrium-90 for colorectal liver metastasis - the promising role of radiation segmentectomy as an alternative local cure","volume":"39","author":"Entezari","year":"2022","journal-title":"Int J Hyperthermia"},{"issue":"5","key":"10.1016\/j.cpet.2024.03.010_bib74","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1016\/j.surg.2020.12.012","article-title":"A\u00a0comparative study of portal vein embolization versus radiation lobectomy with Yttrium-90 microspheres in preparation for liver resection for initially unresectable hepatocellular carcinoma","volume":"169","author":"Bekki","year":"2021","journal-title":"Surgery"},{"issue":"4","key":"10.1016\/j.cpet.2024.03.010_bib75","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1055\/s-0039-1696648","article-title":"Modified radiation lobectomy: an evolving paradigm to convert patients to liver resection candidacy","volume":"36","author":"Gabr","year":"2019","journal-title":"Semin Intervent Radiol"}],"container-title":["PET Clinics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1556859824000257?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1556859824000257?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,7,3]],"date-time":"2024-07-03T20:39:26Z","timestamp":1720039166000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1556859824000257"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7]]},"references-count":75,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2024,7]]}},"alternative-id":["S1556859824000257"],"URL":"https:\/\/doi.org\/10.1016\/j.cpet.2024.03.010","relation":{},"ISSN":["1556-8598"],"issn-type":[{"value":"1556-8598","type":"print"}],"subject":[],"published":{"date-parts":[[2024,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Hepatic Radioembolization","name":"articletitle","label":"Article Title"},{"value":"PET Clinics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cpet.2024.03.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}